Blood thinner may boost survival in High-Risk pregnancies
NCT ID NCT07462182
First seen Mar 22, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study tests whether enoxaparin, a blood thinner, can improve survival and reduce complications in babies diagnosed with intrauterine growth restriction (poor growth) and oligohydramnios (low amniotic fluid). About 108 pregnant women will receive either enoxaparin or standard care. The goal is to see if the treatment increases live births and lowers the need for intensive care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAUTERINE GROWTH RESTRICTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Combined Military Hospital
Quetta, Balochistan, 80000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.